Lineage Cell Therapeutics updates bylaws and holds shareholder meeting By Investing.com

Lineage Cell Therapeutics (NYSE:), Inc. (NYSE American: LCTX), a biotechnology firm specializing in cell-based therapies, announced amendments to its bylaws and the results of its annual shareholder meeting, according to a recent SEC filing.

The Carlsbad, California-based company, formerly known as BioTime Inc., stated on June 11, 2024, that its Board of Directors had approved and adopted the Amended Bylaws. These changes incorporate current provisions of the California Corporations Code and include updates to electronic transmission of board and shareholder meetings, emergency meeting procedures, and the issuance and replacement of stock certificates in book-entry form.

Additionally, the amendments updated advance notice procedures for shareholder nominations and proposals. Noteworthy changes include a requirement for shareholders nominating directors to provide evidence of compliance with SEC Rule 14a-19 and a prohibition on nominating more directors than are up for election at the meeting. The amendments also refined the information and timelines associated with shareholder proposals and director nominations.

The election of board members was met with a significant majority of votes in favor, with broker non-votes accounting for a notable portion of the total. The appointment of the accounting firm and the executive compensation matter also passed with substantial majorities.

The detailed voting results for each director nominee and the two additional proposals were provided in the SEC filing, reflecting a transparent governance process.

These corporate governance updates and shareholder decisions are part of Lineage Cell Therapeutics’ ongoing efforts to align with legal requirements and best practices. The information regarding these changes is based on the company’s recent SEC filing.

In other recent news, Lineage Cell Therapeutics reported encouraging results from its OpRegen treatment for dry age-related macular degeneration (AMD (NASDAQ:)) during an earnings call. Patients demonstrated an average gain in visual acuity, a stark contrast to the typical loss seen with other treatments. The company also announced a new services agreement with Genentech for the further development of OpRegen.

Lineage is gearing up for a new clinical trial for its spinal cord injury program, OPC1, featuring a novel delivery system. Despite a reported quarterly net loss of $6.5 million, the company remains adequately capitalized. CEO Brian Culley drew parallels between the progress of OpRegen and LASIK surgery, suggesting the treatment could become more routine with experience.

InvestingPro Insights

As Lineage Cell Therapeutics, Inc. (NYSE American: LCTX) continues to refine its corporate governance, a look at the company’s financial health and market performance provides additional context for investors. According to real-time data from InvestingPro, LCTX has a Price/Book ratio of 3.78, indicating the market values the company at nearly four times its book value. Despite challenges, with a gross profit margin exceeding 100% in the last twelve months as of Q1 2024, the company demonstrates its ability to maintain high gross profitability.

InvestingPro Tips suggest caution for investors, highlighting an expected decline in sales and net income for the current year. Analysts do not foresee profitability for LCTX this year, and the stock is currently trading at a high revenue valuation multiple. On the upside, the company’s liquid assets surpass short-term obligations, and it operates with a moderate level of debt, which could provide some financial stability in the near term.

For those considering an investment in Lineage Cell Therapeutics, it’s worth noting the company does not pay dividends, which may influence investment decisions for income-seeking shareholders. Those interested in a deeper analysis can find additional InvestingPro Tips for LCTX at https://www.investing.com/pro/LCTX. For access to these insights, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. There are a total of 8 additional InvestingPro Tips available for LCTX that could further inform investment strategies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.